134 related articles for article (PubMed ID: 15373172)
1. [Contribution of fluorescence immunocytochemistry (uCyt+TM) in the postoperative surveillance of bladder cancer].
Piaton E; Ruffion A; Collet F; Lopez JG; Champetier D; Hoch M; Perrin P; Devonec M
Prog Urol; 2004 Jun; 14(3):315-9; discussion 319. PubMed ID: 15373172
[TBL] [Abstract][Full Text] [Related]
2. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravesical instillation on performance of uCYT+ test.
Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
[TBL] [Abstract][Full Text] [Related]
4. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder.
Mian C; Lodde M; Comploj E; Palermo S; Mian M; Maier K; Pycha A
Anticancer Res; 2005; 25(5):3641-4. PubMed ID: 16101194
[TBL] [Abstract][Full Text] [Related]
5. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
6. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses.
Mian C; Maier K; Comploj E; Lodde M; Berner L; Lusuardi L; Palermo S; Vittadello F; Pycha A
Cancer; 2006 Feb; 108(1):60-5. PubMed ID: 16411183
[TBL] [Abstract][Full Text] [Related]
7. [Value of the uCyt+ test for the detection and followup of bladder tumors].
Drapier E; Renaudin K; Maillet F; Braud G; Laboisse C; Bouchot O
Prog Urol; 2003 Apr; 13(2):222-6. PubMed ID: 12765055
[TBL] [Abstract][Full Text] [Related]
8. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
9. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
10. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
11. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
Bergman J; Reznichek RC; Rajfer J
BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
[TBL] [Abstract][Full Text] [Related]
12. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
[TBL] [Abstract][Full Text] [Related]
13. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
[TBL] [Abstract][Full Text] [Related]
14. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
15. [ImmunoCyt--a new urine test in diagnosis of bladder cancer].
Feil G; Bichler KH; Päulgen-Nelde HJ; Hennenlotter J; Zumbrägel A; Stenzl A
Urologe A; 2003 Apr; 42(4):531-7. PubMed ID: 12715125
[TBL] [Abstract][Full Text] [Related]
16. [Determination of NMP-22 as recurrence marker in bladder cancer. Preliminary study].
Pérez García FJ; Escaf Barmadah S; Fernández Gómez JM; Rodríguez Martínez JJ; Martín Benito JL
Arch Esp Urol; 2000 May; 53(4):305-12. PubMed ID: 10900760
[TBL] [Abstract][Full Text] [Related]
17. Immunocytology in the assessment of patients with painless gross haematuria.
Schmitz-Dräger B; Tirsar LA; Schmitz-Dräger C; Dörsam J; Bismarck E; Ebert T
BJU Int; 2008 Feb; 101(4):455-8. PubMed ID: 18005211
[TBL] [Abstract][Full Text] [Related]
18. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
[TBL] [Abstract][Full Text] [Related]
20. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses.
Comploj E; Mian C; Ambrosini-Spaltro A; Dechet C; Palermo S; Trenti E; Lodde M; Horninger W; Pycha A
Cancer Cytopathol; 2013 Jul; 121(7):392-7. PubMed ID: 23495066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
